KRT87P

Across TCGA pan-cancer cohorts, KRT87P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRT87P data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher KRT87P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT87P expression acts as an unfavorable survival marker.

DLBC, LUAD, and BRCA are the cancer types where KRT87P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
LUAD	DFS	Median	All	0.213	0.676	.012	6	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KRT87P–DLBC (OS)

Open the DLBC breakdown →